Introduction
============

Small non‐coding RNAs and especially microRNAs (miRNAs) have been recently identified as key regulators of several cellular processes in multicellular eukaryotes ([@b34]). Massive resources are now allocated to understand this extra layer of gene regulation. Involvement of miRNA expression in different types of tumours (e.g. breast, colon or brain cancer) has been reported ([@b34]; [@b86]). Consequently, blocking of miRNAs has become of therapeutic interest for tumour treatment ([@b24]; [@b86]). In addition, miRNA profiles are now considered as a new tool for diagnostics. Although miRNA profiles contain much less information than an mRNA profile, the potential value may be higher because of the regulatory role of miRNAs ([@b24]).

In bacteria, small RNAs (sRNAs) have attracted considerable attention as an emerging class of new gene expression regulators. Apart from open reading frames, the genome codes for a number of RNAs with non‐coding functions such as rRNAs, tRNAs, and some small non‐coding RNAs, which may act as regulators of transcription or translation and influence mRNA stability ([@b135]). Although the majority of sRNAs might indeed be non‐coding, there are sRNAs, which have both a coding and a non‐coding function ([@b53]).

Small RNAs interact by pairing with other RNAs, forming parts of RNA--protein complexes, or adopting structures of other nucleic acids ([@b117]). A toolbox of experimental technologies such as microarray detection, shotgun cloning (RNomics), co‐purification with proteins and algorithms to predict sRNAs have been established for Gram‐negative bacteria such as *Escherichia coli* ([@b111]). Investigation of the role of sRNAs for other Gram‐negative pathogens such as *Salmonella typhimurium* and *Pseudomonas aeruginosa* has recently been started ([@b111]). sRNAs were detected within genetic islands of *S.  typhimurium*, which showed host‐induced expression in macrophages and thus contributed to virulence ([@b91]).

Recently, an extended number of 103 sRNAs was described for *Listeria monocytogenes* ([@b19]; [@b75]; [@b88]; [@b124]). Only two sRNAs have been identified and studied in some detail in *Streptococcus pyogenes* ([@b61]; [@b76]) and five sRNAs for *Streptococcus pneumoniae* ([@b47]). A first approach identified 12 sRNAs in *Staphylococcus aureus*, seven of which are localized on pathogenicity islands. Some of the sRNAs show remarkable variations of expression levels among pathogenic *S. aureus* strains, which suggest their involvement in the regulation of virulence factors ([@b96]). Presently, there is no information available for sRNAs from *Clostridium difficile* and *Enterococcus faecalis.*

To date, sRNAs have been found to be implicated in stress response, iron homeostasis, outer membrane protein biogenesis, sugar metabolism and quorum sensing, suggesting that they might also play an essential and central role in the pathogenicity of many bacteria. A global approach to identify sRNAs in *L. monocytogenes* has been recently published ([@b124]), but genome‐wide approaches to elucidate the functional role of sRNAs for other high‐risk Gram‐positive pathogens in pathogenicity are limited.

To address this deficiency, we recently established a European consortium ([http://www.pathogenomics‐era.net/2ndJointCall/](http://www.pathogenomics‐era.net/2ndJointCall/)) to perform comparative global analysis of sRNAs for *L. monocytogenes*, *S. aureus*, *S. pyogenes*, *E. faecalis* and *C. difficile*. In this project, we will utilize bioinformatics, novel high‐throughput sRNA screening methods, whole‐genome transcriptomics and proteomics, coupled with existing robust molecular characterization methods to provide new information regarding production, regulation and pathogenic implications of sRNAs in these five major high‐risk Gram‐positive pathogens on a global scale.

These analyses will help us to design novel potential therapeutics based on sRNA‐complementary peptide nucleic acids (PNAs). Furthermore, the knowledge about sRNA expression will be used to develop a novel ultra‐sensitive diagnostic system, which has been conceived for detection of small target samples at extremely low concentrations in a very short time.

Listeria monocytogenes
======================

*Listeria monocytogenes* is an opportunistic facultative intracellular bacterium which is ubiquitously distributed in nature. This food‐borne pathogen belongs to the group of bacteria with low G + C DNA content which also includes other species of genera such as *Streptococcus*, *Staphylococcus*, *Enterococcus* and *Clostridium*. The genus *Listeria* consists of seven different species, namely *Listeria monocytogenes*, *Listeria ivanovii*, *Listeria innocua*, *Listeria welshimeri*, *Listeria seeligeri*, *Listeria grayi* and *Listeria marthii* ([@b45]; [@b40]), of which *L. ivanovii* is predominantly a serious animal pathogen while *L. monocytogenes* can cause fatal infections in humans and animals. With regard to its transmission, a majority of listerial cases have been documented through contaminated food products. The major clinical symptoms exhibited by this pathogen in humans include meningitis, septicaemia, abortion, prenatal infection and gastroenteritis. In spite of an appropriate antibiotic therapy, approximately 20--30% of deaths have been reported in patients suffering from listeriosis ([@b50]).

A hallmark of this human pathogen is its ability to invade and survive inside vertebrate and invertebrate host cells, wherein the bacterium can freely multiply within the cytosol and can induce actin‐based movement and cell‐to‐cell spreading. Prior to infection, Internalin A and B induce the first step of the infection process by interacting with the eukaryotic host cell and promote intracellular uptake of the pathogen after binding with E‐Cadherin and c‐Met as interacting receptors in mammals. However, the main virulence genes, responsible for the intracellular life cycle of *L. monocytogenes*, are clustered in a ∼9 kb chromosomal region ([@b45]; [@b21]).

Over the last decade, regulatory RNA elements have gained increasing importance in the physiology and pathogenesis of prokaryotes. They are divided into two major groups based on their mode of action: *cis* (untranslated region, UTR) and *trans* acting regulatory RNAs (small non‐coding RNAs). Riboswitches and RNA thermometers ([@b85]) belong to the class of *cis* acting regulatory RNAs located at the 5′UTR of their genes. In general, riboswitches modulate their regulatory structure in response to metabolite binding, which are available in their own environment whereas, RNA thermometers are involved in sensing global signals, e.g. the intracellular temperature. Both *cis* regulatory RNA structures are essential for fine regulatory tuning so as to ensure an immediate physiological response of the bacterial cell to a varying habitat.

The first *cis* regulatory RNA was described for the master virulence regulator PrfA ([@b54]). This 5′UTR acts as RNA thermometer which is turned off under low‐temperature conditions. In addition, the importance of 5′UTRs has also been reported for other virulence genes ([@b137]; [@b112]; [@b119]). In general, the effects of UTRs on the expression of ActA, Hly and InlA were analysed by deleting the 5′UTR, while their ribosome binding sites were retained. Further computational analysis has revealed the presence of putative UTRs in surface proteins encoding operons associated with virulence in *L. monocytogenes* and suggests a potential post transcriptional function for these long RNA sequences in pathogenesis ([@b73]).

The role of *trans* regulatory RNAs such as small non‐coding RNAs has been addressed recently. The housekeeping sRNA 4.5S which binds to the signal recognition particle (SRP) was the first sRNA identified in *L. monocytogenes* ([@b1]). SRPs are highly conserved in most bacteria and are involved in translation and targeting of proteins for cellular secretion.

In *L. monocytogenes*, the RNA chaperone Hfq is involved in stress tolerance and virulence ([@b18]). In order to investigate sRNA--Hfq interaction, a co‐immunoprecipitation approach identified three Hfq‐binding sRNAs (*lhrA*, *lhrB* and *lhrC*; *lhrC* reveals five copies in the chromosome), which are growth phase‐dependently expressed and induced during intracellular multiplication within HepG2 cells. In a later study, new algorithms were used to predict and functionally map novel sRNA for *L. monocytogenes*. This allowed the identification of 12 additional sRNA (*rliA--I*, *ssrS*, *ssrA* and *rnpB*), and for three of them (*rliB*, *rilE* and *rliI*), potential mRNA targets were predicted *in silico* and experimentally verified ([@b75]).

*Listeria monocytogenes* is well known for its robust physiology because of its capability to grow under refrigeration temperature, low pH and also at high osmolarity. However, relatively little is known about the role of sRNA for the adaptive physiological response in promoting survival and growth of the bacterium in such hostile environments. Besides, the involvement of the alternative sigma factor σ^B^ in the regulation of sRNA was elucidated not until recently when a 70‐nt‐long sRNA (*sbrA*) was identified which was reported to be under control of this stress tolerance factor ([@b88]).

In order to study global transcriptional profiling in response to the changing environmental niche of the pathogen, several different stress and *in vitro/in vivo* infection conditions were exploited using genome‐wide microarray approaches ([@b55]; [@b128]; [@b46]; [@b98]; [@b12]). We have used transcriptome profiling to examine the expression profile of *L. monocytogenes* inside the vacuolar and the cytosolic environments of the host cell using whole‐genome microarray and mutant analysis. We found that ∼17% of the total genome was mobilized to enable adaptation to intracellular growth ([@b17]), but the role of sRNA during host cell infection was not addressed in this study.

A first genome‐wide approach has been recently reported by [@b124]) using tiling arrays to detect novel sRNA. Thus, the transcriptional profile of *L. monocytogenes* was analysed under several different conditions including bacteria growing in BHI exponentially as well as to the stationary phase, under low oxygen and temperature (30°C), in the murine intestine and human blood and compared with the transcriptome of Δ*prfA*, Δ*sigB* and Δ*hfq* isogenic mutants. Under these conditions a complete operon map with 5′ and 3′ end boundaries was determined as well as 103 small regulatory RNA were identified ([Table 1](#t1){ref-type="table"}). Among the regulatory RNAs, 29 novel sRNAs, 13 *cis* regulatory RNAs (5′‐ and 3′UTR, putative riboswitches) and 40 *cis* regulatory RNAs including known riboswitches were identified. Isogenic mutant analyses of *rliB* and *rli38* indicated their contribution in virulence in mice. This initial study describes the global transcriptional landscape in *L. monocytogenes* under various growth conditions and provides insights into strategies of extracellular survival of the human pathogen. Nevertheless, details on the precise role of sRNAs in the pathogenesis of *L. monocytogenes* remain limited and additional studies on physiological function are needed in order to understand the sRNA regulatory function.

###### 

Current overview of published Gram‐positive sRNAs of the genera *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium* and *Listeria*.

  Genus                        Species        SIPHT[a](#t1n1){ref-type="table-fn"}   Experimentally verified                                                 
  ---------------------------- -------------- -------------------------------------- ----------------------------------- ----------------------------------- ----------------------------------
  *Staphylococcus*             *aureus*       32--79 (12)                            0--5 (9)                            23[b](#t1n2){ref-type="table-fn"}   1[c](#t1n3){ref-type="table-fn"}
  *epidermidis*                116--127 (2)   0--4 (7)                                                                                                       
  *haemolyticus*               74 (1)         --                                                                                                             
  *saprophyticus*              38 (1)         1 (2)                                                                                                          
  *Streptococcus*              *agalactiae*   29--34 (3)                             --                                                                      
  *mutans*                     18 (1)         --                                                                                                             
  *pneumoniae*                 28--66 (3)     --                                     5[d](#t1n4){ref-type="table-fn"}                                        
  *pyogenes*                   18--29 (12)    --                                     3[e](#t1n5){ref-type="table-fn"}                                        
  *thermophilus*               31--36 (3)     0 (2)                                                                                                          
  *sanguinis*                  34 (1)         --                                                                                                             
  *suis*                       23--24 (2)     --                                                                                                             
  *Enterococcus Clostridium*   *faecalis*     14 (1)                                 0--2 (3)                                                                2[f](#t1n6){ref-type="table-fn"}
  *acetobutylicum*             18 (1)         2 (1)                                  1[g](#t1n7){ref-type="table-fn"}                                        
  *beijerinckii*               31 (1)         --                                                                                                             
  *botulinum*                  54--68 (4)     0 (2)                                                                                                          
  *difficile*                  2 (1)          0 (1)                                                                                                          
  *kluyveri*                   46 (1)         0 (1)                                                                                                          
  *novyi*                      26 (1)         --                                                                                                             
  *perfringens*                14--18 (3)     0--2 (3)                               1[h](#t1n8){ref-type="table-fn"}                                        
  *tetani*                     45 (1)         0 (1)                                                                                                          
  *thermocellum*               6 (1)          --                                                                                                             
  *Listeria*                   *innocua*      115 (1)                                2 (1)                                                                   
  *monocytogenes*              94--124 (2)    --                                     27[i](#t1n9){ref-type="table-fn"}                                       
  *welshimeri*                 100 (1)        --                                                                                                             
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The SIPHT columns show the minimum and maximum number of annotated sRNAs of each species.

The quantity of analysed strains is depicted in brackets.

Staphylococcus aureus
=====================

*Staphylococcus aureus* is one main cause of nosocomial infections worldwide. Because of the high occurrence of multiple resistant strains in hospital settings, infections caused by this pathogen are often difficult to treat and new therapeutic strategies are urgently needed. The post genomic era of *S. aureus* started in 2001 with the publication of the genome sequences of two strains, N315 and Mu50 ([@b64]). In the *S. aureus* N315 genome, 110 non‐coding RNAs are annotated. Among them are 78 tRNAs and rRNAs and 32 putative sRNAs and riboswitches ([@b36]).

A large number of virulence factors are known to be involved in the pathogenesis of *S. aureus* whose expression is subject of temporal control and mainly affected by RNAIII. RNAIII was the first regulatory RNA shown to be involved in bacterial virulence and is part of the *agr* locus in *S. aureus* that acts as a quorum sensing system ([@b99]; [@b89]; [@b53]) RNAIII is a 514 nt regulatory RNA and controls the switch between production of cell wall adhesins and that of extracellular proteins ([@b28]; [@b138]). The mechanism by which RNAIII regulates such a large number of genes has been unknown for a long time. In the meantime, a direct regulatory effect of RNAIII has been shown for *hla* expression ([@b82]) and for *spa* expression ([@b51]). However, RNAIII possibly affects the expression of most of the virulence genes in *S. aureus* indirectly via the pleiotropic regulator Rot (for repressor of toxins). RNAIII antagonizes Rot activity by blocking its synthesis, with RNAIII acting as an antisense RNA, pairing with complementary regions in the 5′ end of *rot* mRNA. Binding of RNAIII induces cleavage of the *rot* transcript ([@b35]; [@b7]).

[@b96]) described the first global approach to identify sRNAs in *S. aureus.* They used a comparative genomic approach to characterize the RNome of *S. aureus* on the basis of the genome sequence of strain N315 and detected at least 12 sRNAs: five are encoded in the core genome and seven are localized on pathogenicity islands. Some of the sRNAs show remarkable variations of expression among pathogenic strains and it is postulated that they might be involved in the regulation of virulence factors as it is described for RNAIII.

Most recently, a more comprehensive search for sRNAs in *S. aureus* was performed by [@b36]). They identified 11 new sRNAs (RsaA to K). Transcriptional analyses using three reference strains of *S. aureus* (RN6390, Newman and COL) also showed different transcription profiles of these sRNAs between the strains. Most of the sRNAs were growth phase‐dependently expressed and transcribed in response to environmental changes such as oxidative stress, heat stress, osmotic stress and acidic pH. Transcription of three of them was mediated by the alternative sigma factor σ^B^ and one was regulated by the quorum sensing system *agr*.

Details on the regulatory function of sRNAs in physiology and pathogenesis of *S. aureus* are still limited. By using transcriptomic and proteomic analyses, [@b36]) have shown that RsaE which was expressed under various stress conditions is involved in the regulation of several genes involved in amino acid and peptide transport, cofactor synthesis, lipid and carbohydrate metabolism and the TCA cycle. RsaE binds to its target mRNAs via a specific sequence motif and inhibits the formation of the translational initiation complex. Direct interactions of RsaE with *oppB*, *sucD* and *SA0873* mRNAs have been shown. The specific sequence motif seems to be highly conserved among sRNAs in *S. aureus* indicating a very similar mode of action ([@b36]).

These studies ([@b96]; [@b36]), however, can only represent the blueprint for the prediction, detection and characterization of sRNAs in *S. aureus.* It can be postulated that the *S. aureus* genome likely codes for more regulatory sRNAs that affect gene expression than have been identified to date. By using tiling DNA arrays and new sequencing techniques, we will certainly get a more comprehensive picture of regulatory sRNAs in *S. aureus* expressed under certain conditions. Characterization of their regulatory role in global gene expression could shed more light on processes of *S. aureus* involved in adaptation to the host environment and pathogenicity and may provide new targets for therapeutic strategies to treat infections caused by this pathogen.

Streptococcus pyogenes
======================

*Streptococcus pyogenes* (group A streptococci, GAS) is another important exclusively human bacterial pathogen. The annual global burden of GAS diseases, including 111 million cases of pyoderma, over 616 million cases of pharyngitis, and at least over 500 000 deaths due to severe invasive diseases, places this pathogen among the most important Gram‐positive bacterial species with major impact in global mortality and morbidity ([@b13]). GAS encodes a large number of virulence factors that are involved in adhesion, colonization, immune evasion and long‐term survival within the host ([@b22]; [@b63; @b62]). For successful adaptation and survival in various targeted host compartments, about 30 orphan transcriptional regulators (RR), together with 13 two‐component signal transduction systems (TCSs) (of which 11 are conserved across all GAS serotypes), sense and integrate the environmental information in GAS ([@b63]; [@b4]; [@b84]).

As in many other bacterial species, a novel level of potential virulence regulation has emerged from the discovery and activity of sRNAs. Two bioinformatics‐based approaches have identified candidate sRNAs in the *S. pyogenes* genome. Livny and colleagues developed SIPTH (sRNA identification protocol using high‐throughput technologies) to identify sRNAs in intergenic loci based on colocalization of intergenic conservation and the presence of Rho‐independent terminators ([@b72]). In order to integrate all available sRNA identification methods we have recently developed MOSES (modular sequence suit), a Java‐based framework, to integrate detection approaches for sRNAs. Using MOSES on the genome sequence of the *S. pyogenes* M49 NZ131 strain we identified four highly probable sRNA candidate genes which were verified by RT‐PCR (P. Raasch, U. Schmitz, N. Patenge, B. Kreikemeyer and O. Wolkenhauer, submitted).

Experimental approaches prior to the availability of tiling array technology allowed identification and partial characterization of three sRNAs (SLS, FasX and RivX) in *S. pyogenes* ([@b61]; [@b76]; [@b104]).

A first GAS sRNA *sagA* was discovered during the identification and functional characterization of the major haemolysin of GAS, streptolysin S (SLS/SagA) ([@b69]; [@b15]). Mangold and colleagues later reported that the mRNA transcribed from the *sls* gene most likely acts as sRNA and effectively regulates expression of *emm* (M protein), *sic* (streptococcal inhibitor of complement) and *nga* (NAD‐glycohydrolase) at the transcriptional level, and expression of SpeB (cystein protease) at the post‐transcriptional level ([@b76]).

The second putative sRNA experimentally identified was *fasX*, a 300‐nucleotide‐long transcript, which is associated with the FasBCAX (fibronectin/fibrinogen binding/haemolytic activity/streptokinase regulator) system ([@b61]).

Measurement of a luciferase--promotor fusion revealed a growth phase‐associated transcription of *fasX* with peak activities during late exponential phase. Mutation of *fasX* uncovered a reduced expression of the secreted virulence factors *sls* and streptokinase (*ska*), and simultaneously a prolonged expression of fibronectin‐ (*fbp54*) and fibrinogen‐binding (*mrp*) adhesins. Analysis of the role of *fasX* in *S. pyogenes* adherence to and internalization into HEp‐2 cells (a human laryngeal carcinoma cell line) revealed that this sRNA apparently promotes high adherence and internalization rates, leading to massive cytokine gene transcription and cytokine release, host cell apoptosis via a novel caspase 2 activation pathway and cytotoxicity ([@b58]). It is evident that the Fas two‐component signal transduction system, with the *fasX* sRNA as its integral and main effector part, mediates virulence gene regulation and could be involved in GAS aggressiveness and local tissue destruction ([@b58]).

Recently, Roberts and Scott showed that *rivX* encodes another sRNA and microarray analysis revealed that products of the *rivRX* locus exert positive control over transcription of members of the Mga regulon ([@b104]).

The first genome‐wide and comprehensive approach to identify novel sRNAs in the M1T1 MGAS2221 *S. pyogenes* strain, using a combination of bioinformatics and intergenic region tiling arrays, was most recently performed by Sumby and colleagues ([@b95]). The tiling array approach identified 40 candidate sRNAs, of which only seven were also identified by the bioinformatics approach of Livny and co‐workers. This small number of cumulatively identified sRNAs stresses the necessity for multifaceted and integrated approaches. Most of the investigated sRNAs varied in their stability and inter‐ and/or intra‐serotype‐specific levels of abundance. Most interestingly, Sumby and colleagues could not confirm earlier results from Mangold and colleagues who postulated a regulatory function for sagA/Pel ([@b76]).

In summary, three candidate sRNAs were identified experimentally, 29 candidate sRNAs were identified by Livny using a bioinformatic approach ([Table 1](#t1){ref-type="table"}), a further four appeared from the novel MOSES sRNA software and 40 (of which only seven matched candidates from the Livny paper) were found by the first tiling array approach performed by Sumby and co‐workers ([@b95]).

Enterococcus faecalis
=====================

*Enterococcus faecalis* is a human commensal and member of the lactic acid bacteria. It can be used as a starter in food industry and for some strains, probiotic effects have been claimed ([@b27]). However, *E. faecalis* is also used as an indicator of faecal contamination and represent one of the principal causes of nosocomial infections ([@b90]). Despite the increasing number of infections due to *E. faecalis*, mechanisms of virulence remain poorly understood. These infections affect mainly young and immuno‐depressed subjects causing endocarditis, meningitis, pneumonias, peritonitis, visceral abscesses, urinary infections and septicaemias ([@b37]). This makes *E. faecalis* an ambiguous microorganism and, consequently, the use of enterococci in the food industry has been viewed more critically ([@b30]). Thus, efforts are urgently needed in order to get a better understanding of the molecular reasons why this normally harmless bacterium can transform into a dangerous pathogen. In this context, analysis of regulation of gene expression is of prime importance.

From the 3337 predicted protein‐encoding open reading frames in *E. faecalis* V583, 214 have or may have regulatory functions ([@b92]) but only few transcriptional regulators have been studied so far. Some of them have been shown to be correlated with stress response and/or virulence such as Fsr, EtaRS, CylR, HypR, PerR or Ers ([@b97]; [@b37]; [@b123]; [@b130]; [@b129]; [@b100]). However, in recent years it has been discovered that not only proteins but also small non‐coding RNAs are key players in the control of bacterial gene expression. At present, only one mechanism based on two sRNAs (RNA I and RNA II), required for the stable inheritance of the plasmid pAD1, has been reported for *E. faecalis* ([@b136]). The two sRNAs are convergently transcribed towards a bidirectional intrinsic terminator. RNA I encodes the Fst toxin the translation of which is inhibited by the interaction with RNA II. RNA II acts then as the antitoxin and is less stable than RNA I. This suggests that in absence of continued transcription from the resident plasmid, RNA I is removed from the complex allowing the translation of *fst* that kills the cell. One recent study shows that the stability of the toxin‐encoding RNA (RNA I) is due to an intramolecular helix sequestering the 5′ end of the RNA ([@b114]).

Recently, an *in silico* study led to the prediction and annotation of 17 further putative sRNA‐encoding genes in *E. faecalis* V583 ([@b72]), 14 on the chromosome and three on plasmids ([Table 1](#t1){ref-type="table"}). However, in comparison with the number of sRNA identified in the same study in model bacteria such as *E. coli* and *Bacillus subtilis*, the number of potential candidates in *E. faecalis* is roughly 10‐fold lower.

Clostridium difficile
=====================

*Clostridium difficile* is currently one of the increasingly important nosocomial pathogens, but also rising are the numbers of human community‐associated infections and animal infections ([@b106]). The disease spectrum ranges from mild diarrhoea to severe forms of colitis, pseudomembranous colitis and bowel perforation. Most of the symptoms can be explained by effects of two large toxins produced by the bacterium, toxin A (TcdA) and toxin B (TcdB). While both toxins, TcdA and TcdB, are well characterized from molecular and biochemical perspective, our understanding on the regulation mechanisms involved in their expression is only partially elucidated ([@b29]). Even less is known about regulation of additional factors influencing the virulence such as binary toxin CDT, adhesion molecules, sporulation properties and antibiotic resistance.

The regulatory role of small non‐coding RNAs was so far not studied or reported in *C. difficile*. Only two candidate loci ([Table 1](#t1){ref-type="table"}) were found in a large computational study by [@b72]). In the same study candidate sRNAs were detected in some other pathogenic and non‐pathogenic *Clostridia*, e.g. *Clostridium tetani*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium novyi* ([Table 1](#t1){ref-type="table"}). None of them is a closer relative to *C. difficile*; however, *C. novyi* has a toxin TcnA that is homologous to *C. difficile* large toxins.

So far, *C. perfringens* is the only pathogenic clostridial species where the role of sRNA was studied in detail ([@b113]). VR‐RNA is a region expressed under the control of the VirR/VirS system. It encodes an RNA molecule involved in regulation of some *C. perfringens* toxins and other virulence factors. This strongly suggests that regulatory mechanism involving sRNA could also be present in other toxigenic *Clostridia* and justifies an extensive search for and characterization of novel sRNAs in *C. difficile*.

Facultative requirement of Hfq for sRNA--mRNA interaction in Gram‐positive bacteria
===================================================================================

The bacterial RNA chaperone Hfq facilitates pairing interactions between sRNAs and their mRNA targets in several bacteria. However, approximately only half of the sequenced bacterial genomes encode a Hfq homologue ([@b120]). Hfq modulates the stability, translation and polyadenylation of many mRNAs in *E. coli* ([@b32]). In *L. monocytogenes*, Hfq is required for several sRNAs (LhrA--C) ([@b19]), whereas other identified sRNAs in the same bacterium are able to interact with their mRNA without the contribution of Hfq ([@b75]; [@b124]). Similar examples from *Vibrio cholerae* (Qrr1--4) illustrate how heterogeneous the role of Hfq can be in sRNA--mRNA‐mediated regulations within the same bacterium ([@b68]).

Although present in *S. aureus*, Hfq seems not to be required for sRNA--mRNA interactions ([@b6]). For the sporogenic bacterium *C. difficile* less is known about the involvement of the clostridial Hfq homologue in the regulation of sRNAs.

Surprisingly, a gene encoding a homologue of the protein Hfq is not present in the in *S. pyogenes* and *E. faecalis* genome sequence ([@b120]). From this finding arose the question of how sRNAs are stabilized and annealed to their targets in this species? It is unlikely that non‐coding RNAs are 'naked' in a cellular environment and are more likely to be associated with RNA‐binding proteins throughout its lifetime ([@b131]). Thus, an important step for the molecular characterization of sRNAs and identification of their targets will also need the discovery of these RNA‐binding proteins in *S. pyogenes* and *E. faecalis*.

Whole‐genome sRNA identification methods
========================================

Small RNAs have been hard to detect both computationally and experimentally. The first sRNAs were discovered four decades ago serendipitously by radiolabelling of total RNA and subsequent isolation via gel separation ([@b49]; [@b41]; [@b52]). The sRNA discovery in bacteria over the last decade has shifted from the direct labelling and sequencing to genome‐wide technologies including, for example, the genomic SELEX approach ([@b74]), collecting of sRNA genes by shotgun cloning (RNomics) ([@b132]), detection of sRNAs by DNA microarrays ([@b109]) and next‐generation sequencing (NGS) technologies to provide new means to sRNA discovery ([@b80]).

DNA microarrays are a powerful tool for screening sRNA genes on a genome‐wide scale. Employing the so‐called tiling array approach for sRNA gene discovery, probes specific to the region of interest have to be designed. These regions can span the whole genome or just the intergenic regions, where most of the currently known bacterial sRNAs are encoded. Critical design parameters are probe length and their overlap. As the probe sequence is defined by the sequence of the genome, options for probe optimization are limited. By varying the probe lengths, minor adjustments of melting temperatures can be obtained. Also incorporation of modified nucleotides, such as locked nucleic acids (LNAs), might result in more uniform melting temperatures. In any case, sensitive labelling and optimized hybridization conditions are essential. Bacterial sRNAs are highly heterogeneous in length (ranging from approximately 35 to several hundred nucleotides) and do not contain a common sequence such as the polyA tail of eukaryotic mRNAs. Therefore, careful size selection ensures that the complexity of the input RNA sample is reduced and excludes RNA species (e.g. mRNA, rRNA) for downstream microarray analysis. As amplification methods tend to be biased, direct labelling is preferred, even though lower signal intensities are obtained. Due to the fact that only a small number of sRNA genes (∼20--150) are expected to be discovered from bacteria, this results in a relatively low number of signals on the tiling microarrays. Therefore, it is vitally important to provide a range of controls upon design of the microarrays to discriminate between signals arising from other RNA species (e.g. mRNA, rRNA, tRNA) or truncated RNA fragments and existing sRNA genes.

Such tiling experiments can also be performed in more than one round, e.g. by running a first 'rough' mapping approach using long probes (around 50‐mer) and then taking promising regions for a second 'fine‐mapping' with shorter probes (around 25‐mer) to narrow down the 5′ and 3′ ends of the sRNA genes. Although such a second round of screening increases confidence, results always have to be verified by independent techniques, such as real‐time PCR, NGS, RACE‐PCR, parallelized gene knock‐outs or microtitre plate‐based phenotype screens ([@b5]).

Microarrays for such tiling experiments are usually not available off the shelf, but need to be individually designed. Systems such as the flexible Febit^®^ microarray technology ([@b2]) however provide cost‐efficient and easy‐to‐use solutions for sRNA genes discovery employing the aforementioned tiling approach.

Next‐generation sequencing technology provides new means in sRNA discovery and gives access to a screenshot of the global transcriptional landscape without complicated cloning ([@b116]; [@b115]). Methods like sRNA sequencing allow for interrogation of the entire small, non‐coding RNA (sRNA) repertoire. It includes a novel treatment that depletes total RNA fractions of highly abundant tRNAs and small subunit rRNA, thereby enriching the starting pool for sRNA transcripts with novel functionality ([@b71]). An additional advantage of the NGS technology is the immediate information about 5′ and 3′ ends of the sRNAs. However, data analysis is still in its infancy and might make data interpretation difficult and the library preparation necessary for NGS might introduce bias. Thus, the combination of both array‐based and NGS approaches appears to be the most promising experimental procedure for genome‐wide identification of novel sRNAs in bacteria.

Computational approaches on genome‐wide sRNA prediction and target identification
=================================================================================

Despite the new era of NGS technologies, the task to search for and predict candidate sRNA genes on genome level remains a challenge and an open problem. Over the last years tremendous progress has been made in this field and sRNA gene prediction has been implemented based on genome scanners or on classifiers. Sequence‐based classifiers use input information such as sequence, motif or alignment to assign a homology‐based label to the output. Genome scanning uses combinations of assumptions and a sliding window to analyse entire genome sequences.

These genome scanning and *ab initio* methods to predict new sRNA candidates are based on the assumptions that structured RNAs have a lower free energy than random sequences ([@b67]). [@b102]) demonstrated that minimum free energy (MFE) difference is not significant enough to be used as a general sRNA discriminator. Taken the fact that MFE calculation is based on base stacking, not only the nucleotide frequency but the di‐nucleotide frequency is of interest ([@b8]; [@b20]). A thermodynamic calculation to predict the MFE is highly affected by an additional or missing nucleotide related to the window size applied for scanning the genome. Combining all the information obtained from all individual windows decreases the problem ([@b3]).

A common way to analyse nucleotide sequences is in terms of its nucleotide composition. This ranges from mononucleotide, di‐nucleotide to *n*‐nucleotide analyses and leads to their frequencies. Applying compositional statistics to predict new candidates was driven by reports that sRNAs have an average of 50% GC content ([@b102]). This has been successfully tested when searching GC‐rich islands in some AT‐rich organisms ([@b57]) and applying di‐nucleotide statistics in other organisms ([@b107]). Also machine learning techniques have been performed to classify a sequence either as a coding or non‐coding RNA sequence ([@b70]).

Comparative methods use genome sequences of two or more related species performing alignments in order to find maximum regions of similarity between them ([@b103]; [@b25]; [@b23]; [@b101]; [@b134]). Once the regions of similarity are identified, either thermodynamic information or covariate analysis can provide more evidence on sRNA assignment ([@b134]; [@b127]).

Since the first experimentally identified sRNA in 1981 ([@b118]; [@b125]), sRNA gene‐finders based on a set of known sequences have been applied to identify genes belonging to the same gene family. Rfam is a collection of multiple sequence alignments, consensus secondary structures and covariance models representing predicted sRNA families. Starting with 25 sRNA gene families in 2003, the Rfam 9.1 release covers 1372 families in January 2009 ([@b42]; [@b33]).

SIPHT is a high‐throughput computational tool focusing on genome‐wide bacterial sRNA prediction and annotation ([@b72]). Candidate sRNA‐encoding loci are identified based on the presence of putative Rho‐independent terminators downstream of conserved intergenic sequences and each locus is annotated for several features, including conservation in other species, association with one of several transcription factor binding sites and homology to any of over 300 previously identified sRNAs and *cis* regulatory RNA elements. The procedure is sufficiently automated to be applied to all available bacterial genomes; however, the requirement for a terminator motif introduces a bias against the significant fraction of RNA elements that are not followed by a detectable terminator.

Phylogenetic analysis is one of the most informative computational methods for the annotation of genes and identification of evolutionary modules of functionally related genes and sequences ([@b93]). Nucleic acid phylogenetic profiling is successfully applied to protein annotation and has recently been applied for high‐throughput sRNA identification and their functional characterization to *S. aureus* ([@b78]).

Given the scores of sRNAs of unknown function, the identification of their cellular targets has become essential and requires both experimental technologies and computational approaches ([@b133]). Mandin and colleagues described such a tool that has been applied successfully in the genome of *L. monocytogenes*, but it is not available as a webserver ([@b75]). TargetRNA is a web tool which uses a dynamic programming algorithm to search each annotated transcript to generate base‐pair‐binding potential of the input sRNA sequence and rank list of candidate genes. Many existing target prediction programs except IntaRNA neglect the accessibility of target sites and intra‐molecular base pairs using free energy of the hybridized duplex to predict the potential target site ([@b11]).

There is no general toolset that provides a comprehensive solution to the prediction of sRNA. A good practice when starting with computational tools is to carefully choose a set of applicable methods with different approaches and compare the results. An example for such an integrative prediction framework and modular sequence suite is MOSES (P. Raasch, U. Schmitz, N. Patenge, B. Kreikemeyer and O. Wolkenhauer, submitted). Finally, we reiterate that while all of the outlined tools predict sRNAs, the planning of experiments and integration of predictions and experimental data is needed for a reliable validation of *in silico* sRNA and target prediction.

In order to streamline and support the iterative processes, the consortium uses a central data management solution for data integration provided by Genedata. The infrastructure platform, based on Genedata Phylosopher^®^ for sharing and interpreting the experimental data, covers the required comparative genomics and cross‐technology approach. Furthermore, the consortium reconstructs genome‐wide regulatory networks and pathogenesis to identify and validate targets for diagnostics and novel anti‐infective therapies within the Genedata platform.

Antisense reagents as an alternative treatment of microbial infections
======================================================================

The growing knowledge on sRNAs in bacteria, their regulatory role and function and their possible involvement in pathogen infection makes this class of molecules extremely interesting as new targets for antisense therapy and drug development.

Antisense therapy is a form of treatment where genes which are known to be causative for a particular disease are inactivated ('turned off') by a small synthetic oligonucleotide analogue (RNA or DNA, 14--25 nt in length). This analogue is designed to bind either to the DNA of the gene and inhibit transcription or to the respective mRNA produced by this gene, thereby inhibiting translation. For eukaryotes, the strand might also be targeted to bind a splicing site on pre‐mRNA ([@b81]). Recently, miRNAs with their regulatory role have gained interest as targets, too ([@b31]). Here, in most cases the oligonucleotide is designed to inhibit micro‐RNA function essentially by a steric block, RNase H‐ and RISC‐independent antisense mechanism through complementary binding to the micro‐RNA sequence.

To date, antisense drugs are studied to treat diseases such as diabetes, different types of cancer, amyothrophic lateral sclerosis, Duchenne muscular dystrophy as well as asthma and arthritis.

Apart from finding suitable and promising targets, the design of such drugs themselves represents another challenge. Issues like *in vivo* stability and efficient cell delivery have high impact on the dose--response relationship and need to be addressed. In order to avoid enzymatic *in vivo* degradation, modified oligonucleotides or completely synthetic analogues are used. For the antiviral Fomivirsen (marketed as Vitravene) ([@b105]; [@b83]), for example, which is the first antisense reagent approved by the FDA (US Food and Drug Administration), a 21‐mer oligonucleotide with phosphorothioate linkages is used. Phosphorothioates are also employed for a few other promising antisense reagents, some of which already entered preclinical trials, such as AP12009 ([@b48]). Nevertheless, this class of compounds exhibits several disadvantages: they have a comparable low binding affinity to complementary nucleic acids and show non‐specific binding to proteins ([@b10]; [@b44]), causing toxic side‐effects that limit many applications. The toxicity is reduced but not absent in second generation antisense agents with mixed backbone oligonucleotides.

Meeting the challenge to find modifications that provide efficient and specific antisense activity *in vivo* without being toxic, a third generation of antisense agents have emerged ([Fig. 1](#f1){ref-type="fig"}). Analogues such as LNAs, phosphorodiamidate morpholino oligomers (PMOs) and PNAs are altogether no substrates for enzymatic degradation and hybridize with exceptional affinity and target specificity, thereby forming duplexes which are even more stable than the respective RNA:RNA duplexes themselves. A short general overview on PNAs, LNAs and morpholinos was published recently ([@b56]).

![Overview of chemical structures of DNA, LNA (locked nucleic acid), PMO (phosphorodiamidate morpholino oligomer) and PNA (peptide nucleic acid).](mbt0003-0658-f1){#f1}

As shown in [Fig. 1](#f1){ref-type="fig"}, LNAs are RNA nucleotide analogues in which the ribose ring is constrained by a methylene linkage between the 2′‐oxygen and the 4′‐carbon, resulting in the locked C3′‐*endo* conformation. The introduction of LNA residues in oligonucleotides stabilizes the LNA:RNA duplex by either pre‐organization or increased base stacking (increasing *T~m~* by 1--8°C against DNA and 2--10°C against RNA by one LNA substitution in an oligonucleotide). This results in increased RNA target accessibility and higher selectivity. In general, for efficient gene silencing *in vitro* and *in vivo*, fully modified or chimeric LNA oligonucleotides (LNA mixmers) have been applied.

Locked nucleic acids and LNA mixmers can be transfected using standard transfection reagents based on ionic interactions of the negatively charged backbone. However, due to the very strong base pairing in LNA:LNA duplexes it is important to design LNAs without extensive self‐complementary sequences or to apply chimeric LNAs (LNA mixmers), thereby diminishing biological stability to some degree. Furthermore, unless very short probes are required, stretches of more than four LNAs should be avoided.

Contrary to LNAs, PMOs and PNAs have a neutral backbone and thereby different physiochemical properties. Here, high specificity and increased duplex stability with RNAs and DNAs are due to the missing interstrand repulsion between the neutral PMOs (or PNAs) and the negatively charged RNA or DNA target. Thus, hybridization is nearly independent of salt concentration because no counter‐ions are needed to stabilize the duplex.

Phosphorodiamidate morpholino oligomers represent the closest relatives to the previously mentioned first‐generation phosphorothioates. But instead of the negatively charged sulfur, they comprise a neutral dimethylamino‐group bound to the phosphor. In addition to their excellent base stacking, standard PMOs are highly soluble in water, but their thermodynamic properties are not well defined, yet.

For PNAs it is the other way round, thermodynamics are well defined, but water solubility is limited, at least for longer purine‐rich oligomers which tend to aggregate. However, water solubility can be adjusted by introduction of one or more lysines which can be easily employed, as PNA synthesis strictly follows Fmoc‐peptide synthesis. PNA is a fully synthetic DNA analogue, which consists of the four nucleobases attached to a neutral peptide‐like amide backbone ([Fig. 1](#f1){ref-type="fig"}). Despite the totally different backbone, PNA hybridizes with very high specificity to RNA and DNA via Watson‐Crick as well as Hoogsteen base pairing. *In vitro* studies indicate that PNAs could inhibit both transcription and translation of genes to which it has been targeted ([@b39]; [@b87]). Due to higher duplex stability, probes can be much shorter in length than DNA probes. Very high chemical as well as biological stability make them excellent probes for antisense drug development and diagnostics.

In summary, LNAs, PMOs and PNAs have great potential as antisense drugs, each of them having its own advantages and draw‐backs. Even though there are some recent reports comparing these analogues in experiments ([@b43]; [@b31]), at the time being, the choice of analogue still depends on the experimental conditions and detailed applications.

For all analogues, cell‐wall permeability is very limited, but cellular uptake can be improved by shortening the length of the antisense oligomer and/or attaching cell‐penetrating peptides (CPPs) ([@b122]; [@b43]; [@b65]) or other modifications which increase uptake ([@b59]; [@b60]). The CPP approach is currently a major avenue in engineering delivery systems that are hoped to mediate the non‐invasive import of cargos into cells. The large number of cargo molecules that have been efficiently delivered by CPPs ranges from small molecules to proteins, oligonucleotide analogues and even liposomes and particles.

To date, the most common reported CPP for bacteria is (KFF)~3~K. It is mainly used in combination with PNAs or PMOs. These compounds show efficient inhibition of gene expression in a sequence specific and dose‐dependent manner at low micromolar concentrations in different bacteria ([@b87]; [@b122]; [@b43]; [@b65]; [@b38]).

The search of efficient CPPs, which may improve cell delivery even further, is still an emerging field of research and has high potential for optimization. As demonstrated recently by Mellbye and colleagues variations in amino acid compositions of CPPs and linker molecules show clear effects on the efficiency of cell delivery ([@b79]). Broader systematic studies like this are still missing, but may open the road to a toolbox of different CPPs with optimized and well‐characterized efficiencies to transfer drugs specifically into different cell types.

Due to similar synthesis methods, PNA--peptide conjugates can easily be produced in microwell plates in a parallel manner ([@b9]), thereby allowing for a fast optimization of the antisense as well as the cell‐delivery sequences for antisense drug design. A proof of principle that these compounds can be used as therapeutic drugs against bacterial infection was demonstrated by [@b122]) in a mouse model. In combination with promising targets such as sRNAs, which are suggested to play a major regulatory role in bacterial pathogenesis, the development of highly efficient antisense drugs becomes feasible as an excellent alternative to classical antibiotic treatment.

sRNAs for microbial diagnosis
=============================

Newly discovered sRNA sequences that were verified to be involved in virulence mechanisms of the different Gram‐positive bacteria may not only be used as potential antisense drugs but also exploited as targets for diagnostic systems.

In this respect sRNAs represent a useful alternative to mRNA or DNA oligonucleotides, because of his putative regulatory function. The potential of this class of compounds as diagnostic markers is currently a very active field of research (Hartmann & Consorten).

Several different formats for rapid diagnostic tests based on nucleic acid interactions have been described in the literature. Many of them are PCR‐based with the Genexpert system produced by Cepheid (Sunnyvale, CA) being the most advanced as it integrates sample preparation, amplification and detection ([@b16]). These methods require experienced personnel and need 30--60 min for an assay to be completed. Therefore they are not suitable for point‐of‐care (POC) testing, the ultimate goal in the development of rapid diagnostic screening tests. An alternative and more cost‐effective approach to nucleic acid testing is the use of a lateral‐flow platform. Lateral‐flow assays (LFAs) were originally developed as immunoassays and combine chromatographic purification with immunodetection at high speed ([Fig. 2A](#f2){ref-type="fig"}). They are very simple in handling and represent the only true POC test up to now ([@b108]).

![A. Schematic outline of a standard lateral‐flow assay device ([@b14]). B. Lateral‐flow assay of sRNA captured by PNAs using superparamagnetic magnet nanoparticles. C. Magnetoresistive detection of captured magnet nanoparticles ([@b126]).](mbt0003-0658-f2){#f2}

Nucleic acid lateral flow uses nucleic acid hybridization to capture and detect the nucleic acid analyte in a manner akin to lateral‐flow immunoassays. The most favourable approach is to immobilize oligonucleotide probes directly onto the nitrocellulose membrane used for the chromatographic step of the LFA. This may be done by covalent chemical bonding or by passive adsorption of an albumin--oligonucleotide conjugate to the membrane.

In principle any detection chemistry used in traditional LFA systems may also be applied for nucleic acid detection. Reverse hybridization enzymatic strip assays are the most advanced methods for the detection of nucleic acid interactions. In these tests, enzyme‐labelled probes are hybridized to complementary nucleic acid target species on the surface of the nitrocellulose membrane. The result is a hapten--antibody--enzyme complex such as for example biotin--streptavidine--alkaline phosphatase. But complex wash and substrate incubation steps are necessary to develop a readable colorimetric signal. This vastly limits the speed and simplicity of the assay and makes the POC use of such a system very difficult to achieve.

As an alternative, bead technologies mainly in the form of nanoparticles were successfully applied to nucleic acid LFAs. In this context, gold nanoparticles are the beads of choice, mainly because of their small size, good visibility and robustness in manufacturing ([@b14]). They can be conjugated with oligonucleotides and labelled with small binding moieties such as biotin. Gold NA‐LFA systems generally use 30--80 nm particles conjugated to an anti‐biotin antibody. This conjugate is complexed with a biotin‐oligonucleotide detection probe and forms a visible red line on the membrane strip when captured by a complementary NA sequence. Typical detection limits of such assay formats are about 2.5 mg DNA ml^−1^ ([@b77]).

A number of methods for improving the sensitivity of nanoparticle NA‐LFA have been investigated. Detection probes may be labelled with multiple hapten moieties to form large signal‐enhancing complexes or make use of DNA dendrimeres, which may result in a detection limit up to 200‐fold lower compared with standard assay conditions ([@b26]). Other approaches use fluorescence labels to achieve a better detection. For example, a dual fluorescein‐biotin‐labelled oligonucleotide probe has been used to detect single‐stranded nucleic acids. However the utility of common fluorophores is limited by high background and the need for a complex reader. These problems may be overcome by the application of quantum dots ([@b66]). They consist of nanometre‐sized semiconductor nanocrystals and have superior fluorescence properties that enable them to emit about 1000‐fold brighter light than conventional dyes. They have narrow, symmetrical emission profiles, but have to be excited with UV light. Especially the development of water‐soluble quantum dots has enabled their use in LFAs. However, the price of these fluorescent nanocrystals is quite high, so that no commercial application has been developed so far.

In summary, specificity, sensitivity and cost‐effectiveness are key issues in the development of new nucleic acid‐based diagnostic systems.

To overcome these problems, we use PNA as capture molecules to increase the specificity of the interaction. The peptide backbone of the nucleic acid derivatives makes them much more stable compared with RNA or DNA ([Fig. 1](#f1){ref-type="fig"}). Therefore they are much easier to handle, a great advantage for the development of an appropriate assay as well as for the shelf half life of the reagents in such a diagnostic kit. Equally important, the loss of the negative charge in the phosphate diester of the standard nucleic acid in PNAs led to a higher binding energy, mainly because electrostatic repulsion between the two strands does not exist in PNA/NA duplexes. This effect largely increases the specificity of the interaction. In fact, the melting temperature of a PNA/DNA duplex was measured to be about 15°C higher compared with an isosequential DNA/DNA duplex ([@b110]).

To increase the sensitivity in the detection of the sRNAs captured by the complementary PNA, we use superparamagnetic nanoparticles combined with a suitable magnetoelectronic device ([Fig. 2B](#f2){ref-type="fig"}). This set‐up offers a number of advantages for LFA‐based POC diagnostic measurements. A comprehensive review on magnetic labelling, detection and system integration has appeared recently ([@b121]). A huge benefit of magnetic labelling and detection over fluorescence labelling and optical detection is that there is usually very little magnetic background present in most samples, thereby making single magnetic particle detection both possible and technically feasible ([@b94]). Nanoscale magnetic beads have been extensively developed over the last decade and are commercially available from a number of sources and in different varieties of sizes and surface chemistry. A prime requirement for use as diagnostic labels is that beads must be paramagnetic or non‐remanent to avoid clustering caused by residual magnetic moment in the absence of magnetic fields. Magnetic nanoparticles used in LFA‐based diagnostic devices are preferred to be single domain and small enough to be superparamagnetic, i.e. the thermal fluctuations at room temperature overcome magnetic anisotropy forces spontaneously randomizing magnetic directions. The beads consist of iron oxide cores coated by organic polymers.

Magnetic detection can be established with a number of different sensor types. The simplest devices are based on Maxwell‐Wien bridges or frequency dependent magnetometers made of LC circuits. With these devices, to our best knowledge, single magnetic particle detection has not yet been accomplished. This goal has however been reached with devices based on superconducting quantum interference devices (SQUID), magnetoresistance or Hall sensors. For an excellent review on magnetic sensing see for example [@b121]). SQUID‐based sensors, although being the most sensitive ones, are not apt for POC applications because they need extensive cooling down to at least N~2~ temperatures (77 K).

A schematic illustration of the concept of magnetic detection in traditional lateral‐flow immunoassays is shown in [Fig. 2C](#f2){ref-type="fig"}. Magnetic beads coated with antibodies bind the analyte and were captured by an appropriate antibody immobilized on a magnetoresistive detector. This way magnetic beads loaded with analyte accumulate on the sensor area. Stray magnetic fields from the beads change the electric resistance of the sensor. This change is used to determine the amount of analyte present in the sample. This detection principle is adapted to PNA as capture molecule and sRNA analyte without great difficulties.

Conclusion
==========

The current knowledge about sRNAs of *S. aureus*, *S. pyogenes*, *E. faecalis*, *C. difficile* and *L. monocytogenes* represents only the blueprint for the prediction, detection and characterization of this group of RNAs and will be extended by the inclusion of additional strains of these five Gram‐positive genomes. Currently (October 2009) genome sequences of 39 *S. aureus*, 14 *S. pyogenes*, 23 *E. faecalis*, 12 *C. difficile* and 24 *L. monocytogenes* strains have become available in the NCBI databases, and more serotype‐ and strain‐specific genome sequences will be analysed in future studies.

*In silico* prediction of sRNA showed that the genus of *Listeria* bears a high number of putative sRNA ([@b72]) compared with other genera such as *Streptococcus*, *Staphylococcus*, *Enterococcus* and *Clostridium* ([Table 1](#t1){ref-type="table"}), which might reflect their potential ubiquitous adaption ability in nature and mammals. Comparative analyses of the recently reported 103 regulatory RNAs of *L. monocytogenes* among the genomes of *S. aureus*, *S. pyogenes*, *E. faecalis* and *C. difficile* revealed that riboswitches seem to be more conserved among these Gram‐positive pathogens than sRNA ([Table 2](#t2){ref-type="table"}). Thus it could be speculated that a common ancient mechanism of *cis* acting RNA regulation might exist in Gram‐positive bacteria, while *trans* acting RNAs might be involved in speciation of bacteria in response to their host adaptation processes.

###### 

Comparative genome analysis of 21 of 100 published listerial sRNAs having orthologues ([@b124]) in *Staphylococcus aureus*, *Streptococcus pyogenes*, *Enterococcus faecalis* and *Clostridium difficile*.

  Regulatory RNA   Length (bp)   Position in *Listeria monocytogenes* EGD‐e (bp)   *Clostridium difficile* 630   *Enterococcus faecalis* V583   *Staphylococcus aureus* COL   *Streptococcus pyogenes* M1 GAS
  ---------------- ------------- ------------------------------------------------- ----------------------------- ------------------------------ ----------------------------- ---------------------------------
  FMN              123           2020609--2020487                                  \+ (2)                        \+                             \+ (2)                        \+
  Glycine          92            1372840--1372931                                  \+                                                           \+                            \+
  L13              53            2685233--2685181                                                                \+                             \+                            
  L19              39            1862308--1862270                                  \+ (4)                        \+                             \+ (9)                        \+
  L21              79            1577146--1577068                                                                \+                                                           
  M‐box            165           2766104--2765940                                                                \+ (5)                                                       
  PreQ1            48            907926--907973                                                                  \+                                                           
  SAM2             120           309385--309266                                    \+ (5)                                                                                     
  SAM3             101           637926--637826                                    \+ (4)                                                                                     
  SAM5             109           1716651--1716543                                  \+                                                           \+                            
  SAM6             107           1739597--1739491                                  \+ (5)                                                                                     
  SAM7             119           2491176--2491058                                  \+                                                                                         
  SRP              333           2784604--2784272                                  \+                                                           \+                            
  glmS             195           756458--756652                                                                                                 \+                            
  rli31            115           597812--597926                                    \+                                                                                         
  rli36            84            859527--859444                                    \+                                                                                         
  rli45            78            2154775--2154852                                                                \+                             \+                            
  rli50            177           2783274--2783098                                                                                               \+                            
  rliD             328           1359529--1359202                                                                \+                             \+                            
  rnpB             385           1965188--1961804                                                                \+                             \+                            \+
  ssrA             367           2510220--2509854                                                                \+                                                           

Comparative analysis of five genomes: *L. monocytogenes* EGD‐e, *C. difficile* 630, *E. faecalis* V583, *S. aureus* COL and *S. pyogenes* M1 GAS.

Genome sequences were downloaded from NCBI <http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi>.

One hundred sRNAs from *L. monocytogenes* EGD‐e ([@b124]) were used as reference and compared against the other four genomes using [blast]{.smallcaps}.

Default settings for [blast]{.smallcaps} were used except reward match penalty (flag‐r), which was set to 2 to accommodate the distant relation among the genomes.

The [blast]{.smallcaps} results were filtered by identity = 30% and query coverage = 50--150%.

Query coverage is defined as the percentage of the sRNA that is covered by the alignment \[(alignment length \* 100)/query length\].

The number of hits is depicted in brackets.

Combating of emerging antibiotic‐resistant microbial strains remains an urgent and continuous task worldwide. Thus the search for novel sRNAs on a global scale is another facet for a better and systematic understanding of the pathogenesis of Gram‐positive bacteria and for the identification of potential novel drug targets and intervention strategies. Newly identified sRNAs are also potential markers and will be used to establish diagnostic tests that are fast, sensitive and suitable for POC applications at low cost.

The most urgent questions for the future will be: (i) what is the mode of action of many of the candidate sRNAs, (ii) how many of them are relevant for pathogenesis and regulatory networks, and most importantly (iii) are some of them targets for novel anti‐infective therapy by PNA technology and (iv) can they be used for the development of novel diagnostic systems.
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